(Q37890759)

24 August 2017

1 reference

title

Current controversies and future perspectives in chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

24 August 2017

0 references

Jørgen Vestbo

2

0 references

author name string

Alvar Agustí

series ordinal

1

1 reference

PubMed ID

21680951

24 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

American Journal of Respiratory and Critical Care Medicine

24 August 2017

1 reference

24 August 2017

184

1 reference

24 August 2017

5

1 reference

24 August 2017

507-513

1 reference

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

24 August 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Epidemiology of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

The natural history of chronic airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Natural histories of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Effects of cigarette smoking on lung function in adolescent boys and girls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Decline of FEV1 by age and smoking status: facts, figures, and fallacies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Early life origins of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Permanent effects of maternal smoking on offsprings' lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Chronic obstructive pulmonary disease phenotypes: the future of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Human disease classification in the postgenomic era: a complex systems approach to human pathobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

The SERPINE2 gene is associated with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Network medicine: a network-based approach to human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Chronic obstructive pulmonary disease in non-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Relation of fetal growth to adult lung function in south India

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

The relationship between pneumonia in early childhood and impaired lung function in late adult life

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

COPD, a multicomponent disease: implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Characterisation of COPD heterogeneity in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Variations of inflammatory mediators and alpha1-antitrypsin levels after lung volume reduction surgery for emphysema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Effects of an integrated care intervention on risk factors of COPD readmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Neutrophils and protease/antiprotease imbalance

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Oxidative stress and airway inflammation in severe exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Enhanced neutrophil response in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Immunologic aspects of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Apoptosis and emphysema: the missing link.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

COPD as a disease of accelerated lung aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Inflammation and repair processes in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Cigarette smoke inhibits alveolar repair: a mechanism for the development of emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Needed—Urgently

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Telomere shortening in smokers with and without COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Chronic Obstructive Pulmonary Disease: Beyond the Forced Expiratory Manoeuvre

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201103-0405PP

10.1164/RCCM.201103-0405PP

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21680951